Rheumatoid Arthritis Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Rheumatoid Arthritis stocks.

Rheumatoid Arthritis Stocks Recent News

Date Stock Title
May 6 REGN Regeneron Announces Investor Conference Presentations
May 6 BMY FDA accepts Bristol Myers application for injected Opdivo
May 6 XNCR Xencor (XNCR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
May 6 REGN Regeneron: Dissecting The First Quarter Results And Regulatory Setbacks
May 6 CANF Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602
May 6 BMY U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)
May 6 BMY European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite...
May 5 REGN Wall Street Breakfast: The Week Ahead
May 4 BMY Pharma R&D productivity seen improving for the first time in years - Deloitte
May 4 REGN 23 Most Profitable Stocks of the Last 12 Months
May 4 BMY Bristol-Myers Squibb (NYSE:BMY) shareholders have endured a 33% loss from investing in the stock a year ago
May 3 XNCR Insider Sale at Xencor Inc (XNCR): EVP, Chief Development Officer Nancy Valente Sells Shares
May 3 REGN Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2024 Earnings Call Transcript
May 3 BMY Could Investing $100,000 in Bristol Myers Squibb Stock Make You a Millionaire?
May 3 REGN Regeneron Pharmaceuticals First Quarter 2024 Earnings: Misses Expectations
May 3 BMY If You'd Invested $1,000 in Bristol Myers Squibb 5 Years Ago, Here's How Much You'd Have Today
May 3 PLX Protalix BioTherapeutics to Announce First Quarter 2024 Financial and Business Results on May 10, 2024
May 3 BMY The Zacks Analyst Blog Highlights Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine
May 3 REGN Regeneron Pharmaceuticals Inc (REGN) Q1 2024 Earnings Call Transcript Highlights: Key Financial ...
May 3 REGN Decoding Regeneron Pharmaceuticals Inc (REGN): A Strategic SWOT Insight
Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a long-term autoimmune disorder that primarily affects joints. It typically results in warm, swollen, and painful joints. Pain and stiffness often worsen following rest. Most commonly, the wrist and hands are involved, with the same joints typically involved on both sides of the body. The disease may also affect other parts of the body. This may result in a low red blood cell count, inflammation around the lungs, and inflammation around the heart. Fever and low energy may also be present. Often, symptoms come on gradually over weeks to months.While the cause of rheumatoid arthritis is not clear, it is believed to involve a combination of genetic and environmental factors. The underlying mechanism involves the body's immune system attacking the joints. This results in inflammation and thickening of the joint capsule. It also affects the underlying bone and cartilage. The diagnosis is made mostly on the basis of a person's signs and symptoms. X-rays and laboratory testing may support a diagnosis or exclude other diseases with similar symptoms. Other diseases that may present similarly include systemic lupus erythematosus, psoriatic arthritis, and fibromyalgia among others.The goals of treatment are to reduce pain, decrease inflammation, and improve a person's overall functioning. This may be helped by balancing rest and exercise, the use of splints and braces, or the use of assistive devices. Pain medications, steroids, and NSAIDs are frequently used to help with symptoms. Disease-modifying antirheumatic drugs (DMARDs), such as hydroxychloroquine and methotrexate, may be used to try to slow the progression of disease. Biological DMARDs may be used when disease does not respond to other treatments. However, they may have a greater rate of adverse effects. Surgery to repair, replace, or fuse joints may help in certain situations. Most alternative medicine treatments are not supported by evidence.RA affects about 24.5 million people as of 2015. This is between 0.5 and 1% of adults in the developed world with 5 and 50 per 100,000 people newly developing the condition each year. Onset is most frequent during middle age and women are affected 2.5 times as frequently as men. In 2013, it resulted in 38,000 deaths up from 28,000 deaths in 1990. The first recognized description of RA was made in 1800 by Dr. Augustin Jacob Landré-Beauvais (1772–1840) of Paris. The term rheumatoid arthritis is based on the Greek for watery and inflamed joints.

Browse All Tags